FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017144297> ?p ?o ?g. }

• W3017144297 abstract "Abstract Intensification by high-dose araC in post-remission (NEJM331:896,1994) or induction (Blood87:1710,1996; Blood88:2841,1996) therapy, and autologous stem cell transplantation (Lancet351:700,1998) are efforts to improve the cure rate in AML. Starting in 1999 the German AMLCG randomized the patients to receive double induction (Blood93:4116,1999) by TAD- HAM (TAD, standard dose thioguanine/araC/daunorubicin; HAM, high-dose araC 3 (age &lt;60y) or 1 (age 60+y) g/m2 x 6 with mitoxantrone) versus HAM-HAM. The 2nd course was initiated on day 21 in all patients of &lt;60 years and in those older patients with residual b.m. blasts. By the same up-front randomization patients &lt;60 years were assigned to post-remission BuCy myeloablative chemotherapy and autologous stem cell transplantation, or to prolonged maintenance by monthly reduced TAD courses (JCO21:4496,2003), whereas all patients of 60+ years went on to maintenance. Each of the two initial randomizations was balanced for the other, and was also balanced for age, de-novo versus secondary AML/high-risk MDS, cytogenetic groups (favorable, intermediate, unfavorable), LDH, and WBC. A total of 1770 patients entered the trial with 840 patients of &lt;60 years and 930 patients of 60+ years, 1324 patients with de-novo AML, 295 patients with AML after MDS, 97 patients with tAML, 54 patients with high-risk MDS. The outcome in the younger and older patients was 70% and 53% CR, 42% and 19% overall survival at 3 years, 40% and 19% relapse-free survival, and 47% and 23% ongoing remissions. The calculated dosage of araC delivered for remission induction differed by factor 2 within each age group. There was, however, no difference in the CR rate, overall survival, relapse-free survival, or remission duration between the two randomized induction arms in any age group. Furthermore, there was no such difference in any risk group defined by de-novo or other AML, favorable or intermediate or unfavorable karyotype, WBC, LDH, and day 16 residual b.m. blasts. Similarly, the randomization to autologous transplantation versus maintenance failed to produce different outcome in any prognostic subgroup. These findings were even true after adjustment for allogeneic stem cell transplantations which were performed with priority in patients having matched family donors. In conclusion, on the basis of age adapted TAD-HAM double induction and prolonged maintenance the cytotoxic potential may have been exhausted and may not be further escalated in any prognostic group of AML. Only novel targeted chemotherapy and optimized conditioning allogeneic stem cell transplantation is expected to contribute additional curative potential to current management for AML." @default.
• W3017144297 created "2020-04-24" @default.
• W3017144297 creator A5014917310 @default.
• W3017144297 creator A5023137678 @default.
• W3017144297 creator A5025105470 @default.
• W3017144297 creator A5025613660 @default.
• W3017144297 creator A5033935778 @default.
• W3017144297 creator A5039428434 @default.
• W3017144297 creator A5041945240 @default.
• W3017144297 creator A5043414993 @default.
• W3017144297 creator A5043530605 @default.
• W3017144297 creator A5048388170 @default.
• W3017144297 creator A5051334364 @default.
• W3017144297 creator A5053094064 @default.
• W3017144297 creator A5057268503 @default.
• W3017144297 creator A5071091625 @default.
• W3017144297 creator A5071987442 @default.
• W3017144297 creator A5086016311 @default.
• W3017144297 creator A5090793417 @default.
• W3017144297 date "2005-11-16" @default.
• W3017144297 modified "2023-10-14" @default.
• W3017144297 title "Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML)." @default.
• W3017144297 doi "https://doi.org/10.1182/blood.v106.11.272.272" @default.
• W3017144297 hasPublicationYear "2005" @default.
• W3017144297 type Work @default.
• W3017144297 sameAs 3017144297 @default.
• W3017144297 citedByCount "0" @default.
• W3017144297 crossrefType "journal-article" @default.
• W3017144297 hasAuthorship W3017144297A5014917310 @default.
• W3017144297 hasAuthorship W3017144297A5023137678 @default.
• W3017144297 hasAuthorship W3017144297A5025105470 @default.
• W3017144297 hasAuthorship W3017144297A5025613660 @default.
• W3017144297 hasAuthorship W3017144297A5033935778 @default.
• W3017144297 hasAuthorship W3017144297A5039428434 @default.
• W3017144297 hasAuthorship W3017144297A5041945240 @default.
• W3017144297 hasAuthorship W3017144297A5043414993 @default.
• W3017144297 hasAuthorship W3017144297A5043530605 @default.
• W3017144297 hasAuthorship W3017144297A5048388170 @default.
• W3017144297 hasAuthorship W3017144297A5051334364 @default.
• W3017144297 hasAuthorship W3017144297A5053094064 @default.
• W3017144297 hasAuthorship W3017144297A5057268503 @default.
• W3017144297 hasAuthorship W3017144297A5071091625 @default.
• W3017144297 hasAuthorship W3017144297A5071987442 @default.
• W3017144297 hasAuthorship W3017144297A5086016311 @default.
• W3017144297 hasAuthorship W3017144297A5090793417 @default.
• W3017144297 hasConcept C126322002 @default.
• W3017144297 hasConcept C141071460 @default.
• W3017144297 hasConcept C143998085 @default.
• W3017144297 hasConcept C2776694085 @default.
• W3017144297 hasConcept C2776863199 @default.
• W3017144297 hasConcept C2778461978 @default.
• W3017144297 hasConcept C2778729363 @default.
• W3017144297 hasConcept C2780923524 @default.
• W3017144297 hasConcept C28328180 @default.
• W3017144297 hasConcept C2911091166 @default.
• W3017144297 hasConcept C54355233 @default.
• W3017144297 hasConcept C71924100 @default.
• W3017144297 hasConcept C86803240 @default.
• W3017144297 hasConcept C90924648 @default.
• W3017144297 hasConceptScore W3017144297C126322002 @default.
• W3017144297 hasConceptScore W3017144297C141071460 @default.
• W3017144297 hasConceptScore W3017144297C143998085 @default.
• W3017144297 hasConceptScore W3017144297C2776694085 @default.
• W3017144297 hasConceptScore W3017144297C2776863199 @default.
• W3017144297 hasConceptScore W3017144297C2778461978 @default.
• W3017144297 hasConceptScore W3017144297C2778729363 @default.
• W3017144297 hasConceptScore W3017144297C2780923524 @default.
• W3017144297 hasConceptScore W3017144297C28328180 @default.
• W3017144297 hasConceptScore W3017144297C2911091166 @default.
• W3017144297 hasConceptScore W3017144297C54355233 @default.
• W3017144297 hasConceptScore W3017144297C71924100 @default.
• W3017144297 hasConceptScore W3017144297C86803240 @default.
• W3017144297 hasConceptScore W3017144297C90924648 @default.
• W3017144297 hasLocation W30171442971 @default.
• W3017144297 hasOpenAccess W3017144297 @default.
• W3017144297 hasPrimaryLocation W30171442971 @default.
• W3017144297 hasRelatedWork W1507489869 @default.
• W3017144297 hasRelatedWork W1963335440 @default.
• W3017144297 hasRelatedWork W1987643237 @default.
• W3017144297 hasRelatedWork W2061201927 @default.
• W3017144297 hasRelatedWork W2090076603 @default.
• W3017144297 hasRelatedWork W2116085973 @default.
• W3017144297 hasRelatedWork W2158022600 @default.
• W3017144297 hasRelatedWork W2327443350 @default.
• W3017144297 hasRelatedWork W4235813248 @default.
• W3017144297 hasRelatedWork W4254627366 @default.
• W3017144297 isParatext "false" @default.
• W3017144297 isRetracted "false" @default.
• W3017144297 magId "3017144297" @default.
• W3017144297 workType "article" @default.